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SAFETY ISSUES WITH IRON SUCROSE
To the Editor:
Recently, Yee and Besarab1 published an in-depth review
article on iron sucrose that I believe may have understated
evolving data relating to safety concerns with the drug.
When administered intravenously, iron treatment has the
potential to cause the circulation of free iron, with a variety
of adverse consequences, including tissue oxidation and
increased risk for infection. Generally, after intravenous
dosing, iron drugs are taken up by cells in the reticuloendothelial system prior to release of iron to transferrin in the
circulation. However, iron sucrose appears to release iron
into the circulation immediately after dosing. Danielson et
al2 found that peak serum iron levels occurred in only 10
minutes, with direct transfer of iron to transferrin. This
creates the potential to “overwhelm” transferrin, leading to
free iron in plasma. In hemodialysis patients treated with
iron sucrose (100 mg), Parkinnen et al3 found serum iron
levels rose almost immediately, leading to free iron in
plasma in 50% of patients. Serum from these patients readily
promoted the growth of staphylococcus epidermidis in vitro.
Adding exogenous transferrin to the patient’s plasma halted
the bacterial growth, demonstrating that free iron was the
culprit causing the bacterial growth.
Kooistra et al4 studied iron sucrose (100 mg) in 10 stable

hemodialysis patients. Serum iron was found to increase
approximately 20-fold and transferrin saturation increased
to over 400%, indicating full saturation with washover of
free iron into the circulation. Indeed, by high-performance
liquid chromatography (HPLC), they found a significant
increase in nontransferrin bound iron. Rooyakkers et al5
administered 100 mg iron sucrose intravenously to normal
volunteers and found a 4-fold increase in nontransferrin
bound iron in plasma, a 53% to 70% increase in superoxide
generation, and a transient significant reduction in flowmediated vasodilatation.
Zager et al6 found that all intravenous iron drugs resulted
in evidence of oxidation. However, it was found that iron
sucrose led to profound cellular toxicity, leading to a nearly
90% decrease in cell viability. The authors believed that
elucidation of reactive oxidation species with mitochondrial
blockade and ATP depletion were the cause.
Tovbin et al7 studied iron sucrose in 19 hemodialysis
patients, finding a 37% increase in advanced oxidation
protein products (AOPP). Drueke et al8 studied 79 hemodialysis patients and found significant evidence for oxidative
stress and acceleration of atherosclerosis in proportion to the
amount of iron sucrose administered over a 12-month period. Triolo et al9 compared iron sucrose to ferric gluconate
in 61 hemodialysis patients, finding that the rate of infections in the iron sucrose treated group was 1 in 10 patientmonths compared to only 1 in 17 patient-months in patients
treated with ferric gluconate. They suggested that free iron
release by iron sucrose may explain the findings.
Taken together, these and other data suggest that (1) iron
sucrose releases iron too rapidly, (2) the rapid iron release
overwhelms transferrin resulting in free iron in plasma, and
(3) the free iron results in oxidative effects and increased
bacterial growth seen in vitro and in vivo. The extent to
which these adverse consequences of iron sucrose treatment
may apply to other intravenous iron drugs is unclear, but
further research is clearly indicated.
Steven Fishbane, MD
Winthrop-University Hospital
Mineola, NY
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In Reply:
Relevant to our review, “Iron sucrose: the oldest therapy
becomes new,”1 Fishbane contends that iron sucrose (IS)
transfers iron directly to transferrin, promulgating oxdative
tissue damage2 and bacterial proliferation.3 These concerns
deserve merit, but may be equally applicable to other parenteral irons, iron dextran (ID), and iron gluconate (IG). Thus,
the fundamental issue is not whether these potential ironrelated hazards are IS-specific, but whether the quality of the
present data surrounding these issues is sufficient to contend
the above for any of the therapeutic irons.
Transferrin “oversaturation” was initially described for
IG4 and stemmed from iron release in plasma from its
drug-ligand,5 thereby rendering transferrin saturation ⬎100%
as it became the sum of transferrin-bound and ligand-bound
iron. This oversaturation is also a function of drug half-life.5
Calculations of oversaturation in the studies of Danielson et
al5 and Kooistra et al6 are flawed as both used the same
recently discredited iron assay that was also used to determine an IS half-life of 6 hours.5 Despite that ID shields iron
to the greatest extent among the irons, it, along with IS and
IG, directly donates iron to transferrin in vitro.7-9 However,
the clinical hazard of this donation is presently unquantified.
Lastly, transferrin oversaturation might actually be attributable to a small proportion of free or loosely bound iron that
is present in parenteral iron.
Nontransferrin bound iron (NTBI) is present in normal
serum, hemachromatosis, and the thalessemias and increases
after parenteral iron administration.9 NTBI clearly increases
following IS delivery in vitro or in vivo, but no “head-tohead” comparative studies among the different preparations
exist that use comparable assay systems.8,11 More importantly, do transferrin-independent iron transport mechanisms
clear NTBI after exposure to parenteral irons, in contradistinction to hemochromatosis where transferrin binding is
continually superseded?
The potential harm of IS as postulated by Parkinnen et al3
and Zager et al2 has not been borne out. The bacteriologic
studies do not unequivocally prove that S epidermidis prolif-
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eration resulted from free iron as bacteria have evolved
unique systems of iron uptake (siderophores) through which
NTBI may be utilized to enhance growth. Moreover, bacterial growth suppression by exogenous transferrin does not
provide clearcut evidence that free iron was present, because
transferrin’s iron association constant is orders of magnitude
greater than any other plasma chelator or transporter. Similarly, iron toxicity in cell culture3 cannot be directly translated to the in vivo circumstance. The iron preparation
concentrations of these in vitro studies exceeds the conventionally achieved in vivo concentrations of IS and IG. The
lowest concentration that was studied is potentially achievable only after a large-dose ID infusion. With regard to the
oxidative effects on proteins and lipids by IS, we believe that
no definitive or extrapolatable conclusions regarding the
relative toxicities of the parenteral irons should be ascertained until direct comparison trials between IG and ID
appear. However, we agree, along with others, that parenteral iron should be withheld from patients with an active
infection or inflammatory process.
Lastly, there is demonstrated clinical safety and efficacy
of IS in high-risk groups. IS has been successfully used as
treatment for rheumatoid arthritis patients10 and ID-sensitive
patients.11 IS has also been used extensively in pediatric
patients and pregnant and postpartum patients.12 The randomized clinical trial study of Kosch et al13 revealed absolutely
no differences in efficacy, toxicity, or complications of IS or
IG, despite the fact that iron sucrose was administered as a
250-mg monthly dose while IG was administered weekly in
62.5-mg doses.
Anatole Besarab, MD
Jerry Yee, MD
Henry Ford Hospital
Detroit, Michigan
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